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Abstract
In this issue of Critical Care, the study from Laterre and
colleagues offers suggestions for the role of clinical evaluation
committees (CECs) in future sepsis trials. Despite encouraging
preliminary results, all randomized controlled trials (RCTs)
devoted to potential compounds in severe sepsis have failed to
show survival benefit. One of the reasons might be related to
RCT-related factors that inevitably occur within a
heterogeneous septic patient population. A patient population
free from confounding events would seem to provide the most
suitable platform upon which to judge therapeutic effect. To
solve this issue, CECs have been introduced into RCTs in
sepsis to ensure uniform data for analysis and to identify such
'optimal cohorts' for which the therapy was initially designed to
treat. More recently, some RCTs have reported positive results
in sepsis. The role of CECs has shifted to become a more
integral part of the detailed analysis of drug safety and efficacy
in large databases, and to identify subgroups of patients in
which a therapy might be less or more effective and/or safe. As
an example, the retrospective analysis by Laterre and colleagues
focuses on patients with severe community-acquired
pneumonia (sCAP) within a large, failed RCT (on recombinant
tissue factor pathway inhibitor (rTFPI)). However, the results
should be interpreted with great caution, and should be viewed
as exploratory and a hypothesis-generating activity. This
question of potential benefit of rTFPI in patients with sCAP will
be definitively answered by the results of the recently completed
RCP.
The study from Laterre and colleagues [1], published in this
issue of Critical Care, offers suggestions for the role of clinical
evaluation committees (CECs) in future sepsis trials. From
1990 to 2000, randomized controlled trials (RCTs) have eval-
uated a variety of potential therapeutic interventions for severe
sepsis. Despite some encouraging results in phase II trials, all
RCTs have failed to show survival benefit based upon inten-
tion-to-treat analyses [2]. The reasons for these disappointing
results might not only reflect the possible lack of efficacy of
each new therapy, but may also be related to RCT-related fac-
tors that inevitably occur within a heterogeneous septic
patient population. Other variables that might occur include
variability of medical management strategies and the fre-
quency of protocol violations. Phase II trials use a small
number of highly motivated and experienced centers that are
less susceptible to confounding events brought about by vari-
ations in clinical practices than international RCTs.
A patient population free from confounding events and studied
in full compliance with the protocol, including strict adherence
to entry criteria, would seem to provide the most suitable plat-
form upon which to judge the therapeutic effect of a new inter-
vention for sepsis. To solve this issue, CECs have been
introduced into RCTs in sepsis [3-7] to ensure uniform data for
analysis and to identify such 'optimal cohorts' for which the
therapy was initially designed to treat. As an example, Sprung
and colleagues [8] showed that the reduction of mortality was
higher in the pre-specified valid cohort than in the overall
intent-to-treat study population (26.5 versus 14.5%) when
using anti-tumor necrosis factor antibodies for sepsis.
More recently, some RCTs have reported positive results in
sepsis [9,10], although these results remain the subject of
much debate [11]. Consequently, the role of CECs has shifted
to become a more integral part of the detailed analysis of drug
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safety and efficacy in large international integrated databases
of several trials [12], and to identify subgroups of patients in
which the therapy might be less [13] or more [14] effective
and/or safe.
As an example, the retrospective review of patient subgroups
reported by Laterre and colleagues [1] is of great interest.
They focus on patients comprising a well defined population at
high risk of death from severe community-acquired pneumonia
(sCAP) within a large, failed RCT on recombinant tissue factor
pathway inhibitor (rTFPI) in severe sepsis. The heterogeneity
related to sources of infection, microorganisms, surgical pro-
cedures and risk of bleeding is considerably reduced in sCAP
when compared to the broad, non-selected, severe sepsis
population.
However, as the authors stress, results from small groups of
retrospectively selected patients should be interpreted with
great caution due to a combination of reduced statistical
power, increased variance, multiplicity, and the play of chance;
therefore, these results should be viewed only as exploratory
and a hypothesis-generating activity. For instance, the signifi-
cant reduction of mortality with rTFPI observed in the sub-
group of sCAP without heparin seems more related to the
unexpected high mortality of the placebo group (51.9%) than
to a low mortality in the treated group (29.3%). This finding is
in agreement with the higher mortality observed in patients on
usual-care heparin at baseline who were randomized to pla-
cebo than those randomized to heparin in the XPRESS trial
assessing the effect of prophylactic heparin in patients with
severe sepsis treated with activated protein C [15].
This question of potential benefit of rTFPI in patients with
sCAP will be definitively answered by the results of the
recently completed phase III CAPTIVATE trial.
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